Record Information |
---|
Version | 5.0 |
---|
Status | Detected but not Quantified |
---|
Creation Date | 2021-09-11 07:49:13 UTC |
---|
Update Date | 2021-09-26 23:02:20 UTC |
---|
HMDB ID | HMDB0250717 |
---|
Secondary Accession Numbers | None |
---|
Metabolite Identification |
---|
Common Name | Momelotinib |
---|
Description | Momelotinib, also known as CYT-387, belongs to the class of organic compounds known as phenylpyrimidines. These are polycyclic aromatic compounds containing a benzene ring linked to a pyrimidine ring through a CC or CN bond. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions. Momelotinib is a moderately basic compound (based on its pKa). Additional potential treatment indications for momelotinib include other myeloproliferative neoplasms, cancer (solid and liquid tumors) and inflammatory conditions. As of 2011, momelotinib is being developed as a drug for myelofibrosis and currently undergoes Phase I/II clinical trials. Momelotinib (INN, formerly GS-0387, CYT-387) is an inhibitor of Janus kinases JAK1 and JAK2, acting as an ATP competitor with IC50 values of 11 and 18 nM, respectively. The drug was originally discovered by Australian drug discovery company Cytopia, then developed by YM BioSciences Inc (since acquired by Gilead Sciences as of 2013). The inhibitor is significantly less active towards other kinases, including JAK3 (IC50 0.16 μM). As of 2016, momelotinib is being investigated for primary myelofibrosis or post-polycythemia vera or post-essential thrombocythemia myelofibrosis (post-PV/ET MF), as well as a treatment for relapsed or refractory metastatic pancreatic ductal adenocarcinoma (in combination with capecitabine and oxaliplatin). This compound has been identified in human blood as reported by (PMID: 31557052 ). Momelotinib is not a naturally occurring metabolite and is only found in those individuals exposed to this compound or its derivatives. Technically Momelotinib is part of the human exposome. The exposome can be defined as the collection of all the exposures of an individual in a lifetime and how those exposures relate to health. An individual's exposure begins before birth and includes insults from environmental and occupational sources. |
---|
Structure | O=C(NCC#N)C1=CC=C(C=C1)C1=CC=NC(NC2=CC=C(C=C2)N2CCOCC2)=N1 InChI=1S/C23H22N6O2/c24-10-12-25-22(30)18-3-1-17(2-4-18)21-9-11-26-23(28-21)27-19-5-7-20(8-6-19)29-13-15-31-16-14-29/h1-9,11H,12-16H2,(H,25,30)(H,26,27,28) |
---|
Synonyms | Value | Source |
---|
N-(Cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide | MeSH | CYT-387 | MeSH | CYT 387 | MeSH | CYT-11387cyt-387GS-0387momelotinib | ChEMBL | Momelotinib | MeSH |
|
---|
Chemical Formula | C23H22N6O2 |
---|
Average Molecular Weight | 414.469 |
---|
Monoisotopic Molecular Weight | 414.180423972 |
---|
IUPAC Name | N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide |
---|
Traditional Name | N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide |
---|
CAS Registry Number | Not Available |
---|
SMILES | O=C(NCC#N)C1=CC=C(C=C1)C1=CC=NC(NC2=CC=C(C=C2)N2CCOCC2)=N1 |
---|
InChI Identifier | InChI=1S/C23H22N6O2/c24-10-12-25-22(30)18-3-1-17(2-4-18)21-9-11-26-23(28-21)27-19-5-7-20(8-6-19)29-13-15-31-16-14-29/h1-9,11H,12-16H2,(H,25,30)(H,26,27,28) |
---|
InChI Key | ZVHNDZWQTBEVRY-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as phenylpyrimidines. These are polycyclic aromatic compounds containing a benzene ring linked to a pyrimidine ring through a CC or CN bond. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organoheterocyclic compounds |
---|
Class | Diazines |
---|
Sub Class | Pyrimidines and pyrimidine derivatives |
---|
Direct Parent | Phenylpyrimidines |
---|
Alternative Parents | |
---|
Substituents | - Phenylmorpholine
- 4-phenylpyrimidine
- 5-phenylpyrimidine
- Benzamide
- Benzoic acid or derivatives
- Benzoyl
- Tertiary aliphatic/aromatic amine
- Dialkylarylamine
- Aniline or substituted anilines
- Aminopyrimidine
- Benzenoid
- Morpholine
- Monocyclic benzene moiety
- Oxazinane
- Heteroaromatic compound
- Tertiary amine
- Amino acid or derivatives
- Secondary carboxylic acid amide
- Carboxamide group
- Azacycle
- Oxacycle
- Nitrile
- Carbonitrile
- Secondary amine
- Ether
- Dialkyl ether
- Carboxylic acid derivative
- Hydrocarbon derivative
- Organonitrogen compound
- Amine
- Organic oxygen compound
- Organooxygen compound
- Organic nitrogen compound
- Organopnictogen compound
- Organic oxide
- Aromatic heteromonocyclic compound
|
---|
Molecular Framework | Aromatic heteromonocyclic compounds |
---|
External Descriptors | Not Available |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Not Available |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | Not Available | Not Available | LogP | Not Available | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | | Show more...
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Momelotinib,1TMS,isomer #1 | C[Si](C)(C)N(CC#N)C(=O)C1=CC=C(C2=CC=NC(NC3=CC=C(N4CCOCC4)C=C3)=N2)C=C1 | 4314.7 | Semi standard non polar | 33892256 | Momelotinib,1TMS,isomer #1 | C[Si](C)(C)N(CC#N)C(=O)C1=CC=C(C2=CC=NC(NC3=CC=C(N4CCOCC4)C=C3)=N2)C=C1 | 4013.4 | Standard non polar | 33892256 | Momelotinib,1TMS,isomer #1 | C[Si](C)(C)N(CC#N)C(=O)C1=CC=C(C2=CC=NC(NC3=CC=C(N4CCOCC4)C=C3)=N2)C=C1 | 5732.6 | Standard polar | 33892256 | Momelotinib,1TMS,isomer #2 | C[Si](C)(C)N(C1=CC=C(N2CCOCC2)C=C1)C1=NC=CC(C2=CC=C(C(=O)NCC#N)C=C2)=N1 | 4199.9 | Semi standard non polar | 33892256 | Momelotinib,1TMS,isomer #2 | C[Si](C)(C)N(C1=CC=C(N2CCOCC2)C=C1)C1=NC=CC(C2=CC=C(C(=O)NCC#N)C=C2)=N1 | 3961.6 | Standard non polar | 33892256 | Momelotinib,1TMS,isomer #2 | C[Si](C)(C)N(C1=CC=C(N2CCOCC2)C=C1)C1=NC=CC(C2=CC=C(C(=O)NCC#N)C=C2)=N1 | 5829.2 | Standard polar | 33892256 | Momelotinib,2TMS,isomer #1 | C[Si](C)(C)N(CC#N)C(=O)C1=CC=C(C2=CC=NC(N(C3=CC=C(N4CCOCC4)C=C3)[Si](C)(C)C)=N2)C=C1 | 4059.2 | Semi standard non polar | 33892256 | Momelotinib,2TMS,isomer #1 | C[Si](C)(C)N(CC#N)C(=O)C1=CC=C(C2=CC=NC(N(C3=CC=C(N4CCOCC4)C=C3)[Si](C)(C)C)=N2)C=C1 | 3920.1 | Standard non polar | 33892256 | Momelotinib,2TMS,isomer #1 | C[Si](C)(C)N(CC#N)C(=O)C1=CC=C(C2=CC=NC(N(C3=CC=C(N4CCOCC4)C=C3)[Si](C)(C)C)=N2)C=C1 | 5202.2 | Standard polar | 33892256 | Momelotinib,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N(CC#N)C(=O)C1=CC=C(C2=CC=NC(NC3=CC=C(N4CCOCC4)C=C3)=N2)C=C1 | 4566.8 | Semi standard non polar | 33892256 | Momelotinib,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N(CC#N)C(=O)C1=CC=C(C2=CC=NC(NC3=CC=C(N4CCOCC4)C=C3)=N2)C=C1 | 4250.6 | Standard non polar | 33892256 | Momelotinib,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N(CC#N)C(=O)C1=CC=C(C2=CC=NC(NC3=CC=C(N4CCOCC4)C=C3)=N2)C=C1 | 5740.3 | Standard polar | 33892256 | Momelotinib,1TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)N(C1=CC=C(N2CCOCC2)C=C1)C1=NC=CC(C2=CC=C(C(=O)NCC#N)C=C2)=N1 | 4472.6 | Semi standard non polar | 33892256 | Momelotinib,1TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)N(C1=CC=C(N2CCOCC2)C=C1)C1=NC=CC(C2=CC=C(C(=O)NCC#N)C=C2)=N1 | 4164.9 | Standard non polar | 33892256 | Momelotinib,1TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)N(C1=CC=C(N2CCOCC2)C=C1)C1=NC=CC(C2=CC=C(C(=O)NCC#N)C=C2)=N1 | 5807.4 | Standard polar | 33892256 | Momelotinib,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N(CC#N)C(=O)C1=CC=C(C2=CC=NC(N(C3=CC=C(N4CCOCC4)C=C3)[Si](C)(C)C(C)(C)C)=N2)C=C1 | 4511.7 | Semi standard non polar | 33892256 | Momelotinib,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N(CC#N)C(=O)C1=CC=C(C2=CC=NC(N(C3=CC=C(N4CCOCC4)C=C3)[Si](C)(C)C(C)(C)C)=N2)C=C1 | 4360.3 | Standard non polar | 33892256 | Momelotinib,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N(CC#N)C(=O)C1=CC=C(C2=CC=NC(N(C3=CC=C(N4CCOCC4)C=C3)[Si](C)(C)C(C)(C)C)=N2)C=C1 | 5176.9 | Standard polar | 33892256 |
| Show more...
---|
Spectra |
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Momelotinib GC-MS (Non-derivatized) - 70eV, Positive | splash10-056r-1609000000-b3ce4ef5ff47b8064d1a | 2021-09-23 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Momelotinib GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Momelotinib 10V, Positive-QTOF | splash10-066r-1118900000-8d9d0c12b438552e6f71 | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Momelotinib 20V, Positive-QTOF | splash10-0a4i-1119100000-c3cb24bf07364e219e04 | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Momelotinib 40V, Positive-QTOF | splash10-03di-1937000000-66f0da3b5a5cd5f5bb42 | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Momelotinib 10V, Negative-QTOF | splash10-03di-1011900000-ce312b92228ee5f3abbe | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Momelotinib 20V, Negative-QTOF | splash10-0il0-6577900000-c69ed3ca28c17c8fdf19 | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Momelotinib 40V, Negative-QTOF | splash10-0a4l-9221000000-3505bb55281da145cc0c | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Momelotinib 10V, Positive-QTOF | splash10-014i-0002900000-34e5bd61581537781328 | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Momelotinib 20V, Positive-QTOF | splash10-0a4i-0009000000-a363b581a4b01df0eec6 | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Momelotinib 40V, Positive-QTOF | splash10-066r-0119000000-d17dc38a141319970da1 | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Momelotinib 10V, Negative-QTOF | splash10-03di-0000900000-c1bcd1b72371ff37327a | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Momelotinib 20V, Negative-QTOF | splash10-01q9-1009500000-819f434b2fd770b414a0 | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Momelotinib 40V, Negative-QTOF | splash10-03di-0000900000-0645ab9815d7628fd8d3 | 2021-10-12 | Wishart Lab | View Spectrum |
| Show more...
---|
Biological Properties |
---|
Cellular Locations | Not Available |
---|
Biospecimen Locations | |
---|
Tissue Locations | Not Available |
---|
Pathways | |
---|
Normal Concentrations |
---|
| |
Blood | Detected but not Quantified | Not Quantified | Not Specified | Not Specified | Normal | | details |
|
---|
Abnormal Concentrations |
---|
| Not Available |
---|
Associated Disorders and Diseases |
---|
Disease References | None |
---|
Associated OMIM IDs | None |
---|
External Links |
---|
DrugBank ID | DB11763 |
---|
Phenol Explorer Compound ID | Not Available |
---|
FooDB ID | Not Available |
---|
KNApSAcK ID | Not Available |
---|
Chemspider ID | Not Available |
---|
KEGG Compound ID | Not Available |
---|
BioCyc ID | Not Available |
---|
BiGG ID | Not Available |
---|
Wikipedia Link | Momelotinib |
---|
METLIN ID | Not Available |
---|
PubChem Compound | 25062766 |
---|
PDB ID | Not Available |
---|
ChEBI ID | Not Available |
---|
Food Biomarker Ontology | Not Available |
---|
VMH ID | Not Available |
---|
MarkerDB ID | Not Available |
---|
Good Scents ID | Not Available |
---|
References |
---|
Synthesis Reference | Not Available |
---|
Material Safety Data Sheet (MSDS) | Not Available |
---|
General References | - Barupal DK, Fiehn O: Generating the Blood Exposome Database Using a Comprehensive Text Mining and Database Fusion Approach. Environ Health Perspect. 2019 Sep;127(9):97008. doi: 10.1289/EHP4713. Epub 2019 Sep 26. [PubMed:31557052 ]
|
---|